fashion -WSS

fashion

author：leisure time 2025-09-29 16:25:44 - browse：89

The Senate has set its eyes on regulating insurance plans for some of the most vulnerable patients in the U.S. — the 12.5 million people eligible for both Medicare and Medicaid.

“They’re a complex group of people with a lot of chronic conditions — mental illness, frailty, disability,” said Jose Figueroa, an internal medicine physician and health policy expert at Brigham and Women’s Hospital. Over a third of these dual-eligible beneficiaries have less than a high school education, and about 90% make less than $20,000 per year.

Just around 15% of beneficiaries are eligible for both Medicare and Medicaid, but they account for a third of these programs’ spending — around $440 billion — and still don’t receive better health care, Sen. Bill Cassidy (R-La.) pointed out in a JAMA viewpoint published earlier this month. “The root cause of worse outcomes despite spending more money is a lack of coordination of care,” Cassidy wrote.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

WSS

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

Having children helps parents live longer, especially after age 80

Liver decline slowed by off

Study gives hint on South Asians’ higher risk of cardiovascular disease

Report cites 'urgent' need to recruit more diverse clinical trial participants

ACIP vaccine advisory panel sees its vacancies filled

knowledge

fashion

hotspot

BioMarin wins approval for gene therapy to treat hemophilia A

At flashy new research hub, AstraZeneca lays out ambitious growth goals

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Too many hospitalized Covid

Cancer drug shortages should be causing more outrage

Reports of telehealth's death have been greatly exaggerated

Drug repurposing or repositioning? The language matters

Why Eli Lilly’s earnings didn’t quite live up to the hype

Trump demands the U.S. pay no more for drugs than other countries … again

Listen: A conversation with researcher Kevin Esvelt on biosecurity

focus

Abbott's new heart device gets FDA advisory panel nod

Why Eli Lilly’s earnings didn’t quite live up to the hype

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Investigation reveals sickle cell patients pressured into sterilizations

Scrutiny of post

As a primary care physician, here's how I hope to partner with AI

focus

knowledge

explore

Wikipedia